This article was originally published in The Tan Sheet
The Doylestown, Penn.-based firm reports a 58.1% increase in net sales for the third quarter to $15.3 mil. from $9.7 mil. in the year-ago period in an earnings announcement Oct. 27. The increase reflects a 85.1% rise in sales in the company's cold remedy segment. Sales for that division "continued to far outpace the growth in its category" for the third consecutive quarter, the firm said, noting that new product extensions of Cold-Eeze contributed to the growth. The segment's expansion also is a result of "the success of strategic advertising and marketing initiatives" and "a notable increase in consumer acceptance and expanded household penetration." Third-quarter net income was $3.0 mil. compared to $177,000 for the same period in 2004...
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.